ES2185900T3 - Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos. - Google Patents

Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos.

Info

Publication number
ES2185900T3
ES2185900T3 ES97900943T ES97900943T ES2185900T3 ES 2185900 T3 ES2185900 T3 ES 2185900T3 ES 97900943 T ES97900943 T ES 97900943T ES 97900943 T ES97900943 T ES 97900943T ES 2185900 T3 ES2185900 T3 ES 2185900T3
Authority
ES
Spain
Prior art keywords
viric
composition
component
profilactic
amiloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97900943T
Other languages
English (en)
Inventor
Sven-Erik Svehag
Ellen Holm Nielsen
Ove Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Profylakse ApS
Original Assignee
Profylakse ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Profylakse ApS filed Critical Profylakse ApS
Application granted granted Critical
Publication of ES2185900T3 publication Critical patent/ES2185900T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN COMPONENTE AMILOIDE P DE LAS PROTEINAS SERICAS, CAPAZ DE FIJAR LOS VIRUS, ESPECIALMENTE LOS MIXOVIRUS, POR EJEMPLO, LOS VIRUS DE LA GRIPE, IMPIDIENDO DE ESE MODO LA TRANSMISION E INFECCION CON TALES VIRUS. SE PREFIERE LA ADMINISTRACION MUCOSA, POR EJEMPLO, SAP INCORPORADO A UNA PULVERIZACION NASAL O GOTAS NASALES. SE PROPORCIONA IGUALMENTE UN PROCEDIMIENTO PARA MEDIR LA FIJACION DEL SAP A LA HEMAGLUTININA DE LOS SUBTIPOS Y CEPAS MAS FRECUENTES DEL VIRUS DE LA GRIPE.
ES97900943T 1996-01-25 1997-01-24 Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos. Expired - Lifetime ES2185900T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK7996 1996-01-25

Publications (1)

Publication Number Publication Date
ES2185900T3 true ES2185900T3 (es) 2003-05-01

Family

ID=8089501

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97900943T Expired - Lifetime ES2185900T3 (es) 1996-01-25 1997-01-24 Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos.

Country Status (10)

Country Link
US (1) US6406698B1 (es)
EP (1) EP0915707B1 (es)
AT (1) ATE226829T1 (es)
AU (1) AU712819B2 (es)
CA (1) CA2247388C (es)
DE (1) DE69716741T2 (es)
DK (1) DK0915707T3 (es)
ES (1) ES2185900T3 (es)
PT (1) PT915707E (es)
WO (1) WO1997026906A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4575897A (en) * 1996-10-11 1998-05-11 Universiteit Utrecht Pharmaceutical and diagnostic use of serum amyloid p component
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CN1301745A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——淀粉样糖蛋白10和编码这种多肽的多核苷酸
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
EP1576368B1 (en) * 2002-12-23 2009-02-18 William Marsh Rice Univeristy Methods and compositions for enhancing fibrocyte formation
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US7592695B2 (en) * 2006-12-11 2009-09-22 Graftech International Holdings Inc. Compound heat sink
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
TW201103972A (en) 2009-04-01 2011-02-01 Solvay Fluor Gmbh Process for the manufacture of etched items
US20100266643A1 (en) * 2009-04-01 2010-10-21 Willett W Scott Pulmonary and nasal delivery of serum amyloid p
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
WO2011133450A2 (en) * 2010-04-19 2011-10-27 Meso Scale Technologies, Llc. Serology assays

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221628A (en) * 1991-03-19 1993-06-22 Northwestern University Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component
US5270052A (en) * 1991-04-19 1993-12-14 New England Medical Center Hospitals, Inc. Methods and compositions for treatment of infection by intracellular parasites
ATE189394T1 (de) * 1991-11-27 2000-02-15 Immtech Int Inc Methode zur behandlung von viralen infektionen
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AU4575897A (en) * 1996-10-11 1998-05-11 Universiteit Utrecht Pharmaceutical and diagnostic use of serum amyloid p component
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same

Also Published As

Publication number Publication date
EP0915707B1 (en) 2002-10-30
AU1438097A (en) 1997-08-20
EP0915707A1 (en) 1999-05-19
DE69716741T2 (de) 2003-06-12
PT915707E (pt) 2003-03-31
CA2247388A1 (en) 1997-07-31
WO1997026906A1 (en) 1997-07-31
AU712819B2 (en) 1999-11-18
DK0915707T3 (da) 2003-03-03
CA2247388C (en) 2009-06-02
ATE226829T1 (de) 2002-11-15
US6406698B1 (en) 2002-06-18
DE69716741D1 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
ES2185900T3 (es) Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos.
AU4358701A (en) Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
EA199901031A1 (ru) Производные бензимидазола
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
PT933993E (pt) Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
ATE476984T1 (de) Behandlung von herpes infektion mit anwendung von immunomodulatore polynukleotide sequenzen
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
WO2001068077A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
BR9913157A (pt) Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
BR9916893A (pt) Tratamento
PT833903E (pt) Vacina multivalente de coroanavirus de bovino e metodo para tratar a infeccao decoronavirus de bovino
SE9200199D0 (sv) Farmaceutisk komposition och dess anvaendning
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.